Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 9/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14519956 | 0.84 | IDUA (0.33) | ADORA3CAPN1CTSBCAPN9MAPK1 | |
| SCHEMBL5392098 | 0.84 | IDUA (0.33) | ADORA3CAPN1CTSBCAPN9MAPK1 | |
| SCHEMBL17484921 | 0.82 | ADORA3 (0.41) | ADORA3CAPN1CTSBCAPN9MAPK1 | |
| SCHEMBL14189087 | 0.78 | ADORA2A (0.41) | ADORA3MAPK1 | |
| SCHEMBL16553551 | 0.75 | ADORA2A (0.41) | ADORA3MAPK1 | |
| SCHEMBL1432239 | 0.75 | ADORA2A (0.41) | ADORA3MAPK1 | |
| SCHEMBL26292937 | 0.75 | HSP90AA1 (0.30) | ADORA3 | |
| SCHEMBL11178934 | 0.75 | CAPN1 (0.67) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL11174784 | 0.73 | CAPN1 (0.65) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL13703576 | 0.73 | MEN1 (0.35) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053410-B2 | Pegylated factor VII glycoforms | NOVO NORDISK HEALTH CARE A/G (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20090227504-A1 | Pegylated Factor VII Glycoforms | NOVO NORDISK A/S (DK) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227504-A1 | Pegylated Factor VII Glycoforms | F7, F13B, F5 | ADORA3 4298/4885CAPN1 2761/4885CTSB 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.